WiersingaWJRhodesAChengACPeacockSJPrescottHC.Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782-793. doi:10.1001/jama.2020.12839.
2.
SheahanTPSimsACLeistSR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. 2020;11:222. doi:10.1038/s41467-019-13940-6.
3.
BeigelJHTomashekKMDoddLE, et al. Remdesivir for the treatment of covid-19—final report. New Engl J Med. 2020;383:1813-1826. doi:10.1056/NEJMoa2007764
4.
Martinez-LopezACuenca-BarralesCMontero-VilchezTMolina-LeyvaAArias-SantiagoS.Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: a guide for the dermatologist. J Am Acad Dermatol. 2020;83(6):1738-1748. doi:10.1016/j.jaad.2020.08.006.
5.
GreinJOhmagariNShinD, et al. Compassionate use of remdesivir for patients with severe covid-19. New Engl J Med. 2020;382:2327-2336. doi:10.1056/NEJMoa2007016.
6.
CastellsMCTennantNMSloaneDE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574-580. doi:10.1016/j.jaci.2008.02.044.
7.
NaranjoCABustoUSellersEM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154.
8.
KangYKwonOYJungH, et al. Breakthrough reactions during rapid drug desensitization: clinical outcome and risk factors. Ann Allergy Asthma Immunol. 2019;123(1):48-56. doi:10.1016/j.anai.2019.05.007.
9.
CernadasJRBrockowKRomanoA, et al. General considerations on rapid desensitization for drug hypersensitivity—a consensus statement. Allergy. 2010;65(11):1357-1366. doi:10.1111/j.1398-9995.2010.02441.x.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
